In a phase 3 clinical trial, patients with HR+/HER2−, PIK3CA-mutated BC who received alpelisib–fulvestrant demonstrated statistically significant and clinically meaningful progression-free survival, compared to those with HR+/HER2−, PIK3CA-mutated BC who received placebo–fulvestrant [44]. Here, PIK3CA is linked to breast cancer.